DiCE Molecules is a biotechnology company utilizing its proprietary DNA-encoded library (DEL) technology, combined with unique structural insights, to generate small molecule antagonists against a range of protein-protein-interface (PPI) targets. The DiCE DEL strategy relies on well-curated libraries of compounds that are customized on a target-by-target basis, allowing the Company to carry out medicinal chemistry on a massive scale—greater than 100,000 unique data points per target. NASDAQ: DICE